首页> 外文OA文献 >Development of hot-melt extrusion as a novel technique for the formulation of oral solid dosage forms
【2h】

Development of hot-melt extrusion as a novel technique for the formulation of oral solid dosage forms

机译:开发热熔挤出技术作为口服固体剂型的新技术

摘要

Hot-melt extrusion (HME) is one of the most widely used technologies in the plastic, rubber and food industries and it has also been extensively explored and used in academia and the pharmaceutical industry over the last decade. This project aims to investigate the efficiency of hydrophilic polymers to enhance the dissolution rate of poorly water-soluble APIs processed by HME. Indomethacin (INM) and famotidine (FMT) were selected as model active substances while polyvinyl caprolactam graft copolymer, Soluplus® (SOL) and vinylpyrrolidone-vinyl acetate copolymer grades Kollidon® VA64 (VA64) and Plasdone® S630 (S630) were used as hydrophilic polymeric carriers. For the purpose of the study, all drug-polymer binary blends at various ratios were processed by a Randcastle single screw extruder. The physico-chemical properties and the morphology of the extrudates were evaluated via x-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and scanning electron microscopy (SEM). INM and FMT exhibited strong plasticization effects at specific concentrations and were found to be molecularly dispersed within the polymer blends. The in vitro dissolution studies showed increased INM/FMT release rates for all formulations compared to that of pure APIs alone. Ibuprofen was also embedded in a methacrylate copolymer (Eudragit® EPO) matrix to produce solid dispersions by hot-melt extrusion processing. The obtained granules were incorporated into orally disintegrating tablets (ODTs). The tablets were developed by varying the ratio of superdisintegrants such as sodium croscarmellose and cross-linked polyvinylpyrrolidone while a direct compression process was used to compress the ODTs under various compaction forces to optimize tablet robustness. The properties of the compressed tablets which included porosity, hardness, and friability and dissolution profiles were further evaluated and compared with commercially available Nurofen® Meltlet ODTs. In vitro dissolution of the extruded ODTs showed rapid release of ibuprofen compared to that of Nurofen® Meltlets. The in vitro and in vivo evaluation of the masking efficiency of hot melt extruded paracetamol (PMOL) formulations was examined. Extruded granules containing high PMOL loadings in Eudragit EPO® (EPO) or Kollidon® VA64 (VA64) were prepared by HME. Similarly propranolol HCl (PRP), diphenhydramine HCl (DPD), cetirizine HCl (CTZ) and verapamil HCl (VRP) were used as model cationic active substances while pH sensitive anionic methacrylic acid based methyl methacrylate coplolymers Eudragit® L100 (L100) and ethyl acrylate copolymer Eudragit® L100-55 (Acryl-EZE®) (L100-55) were used as polymeric carriers in order to produce taste masked extruded formulations determining drug-polymers intermolecular interactions. The taste masking effect of the processed formulation was evaluated in vivo by a panel of six healthy human volunteers. In addition, in vitro evaluation was carried out by an Astree e-tongue (Alpha MOS) equipped with seven sensors and Taste Sensing System TS5000Z (INSENT), respectively.ududThe taste and sensory evaluation in human volunteers demonstrated that the formulation masked the bitter taste of the APIs and improved tablet palatability. In addition to that the taste sensing technology demonstrated taste improvement for all polymers by correlating the data obtained for the placebo polymers and the pure APIs alone. The e-tongue results were in good agreement with the in vivo evaluation. Molecular modelling (Gaussian 09) predicted the existence of two possible H-bonding types while Fourier Transform Infra-Red (FT-IR) and NMR studies confirmed drug-polymer interactions between the functional groups of both components (cationic drugs–anionic polymers). Furthermore, the intermolecular interactions evaluated by Flory-Huggins interaction parameters theory and X-ray photoelectron spectroscopy (XPS) showed stronger interactions between drug-polymer in L100 systems compared to that of L100-55 systems. The mechanism of the intermolecular interactions derived from this research showed the presence of H bonding between the amine group of the active substances and the carboxylic groups in the polymer.ududHydrocortisone (HCS) was also embedded and extruded with ethyl cellulose N10 (EC N10) or ethyl cellulose Premium 7 (EC P7) in order to develop sustained release tablets processed by HME. The compressed tablets were subsequently coated with an enteric coating polymer, Eudragit® S100 (15-20%), which showed sustained release over 12 hrs with a lag time of 2 hrs. Further analysis of the release mechanism of HCS from tablets was performed by implementing five different kinetic release models which confirmed that the release of HCS from both coated and uncoated tablets followed a first order kinetic model.
机译:热熔挤出(HME)是塑料,橡胶和食品工业中使用最广泛的技术之一,并且在过去的十年中,它也在学术界和制药行业得到了广泛的探索和使用。该项目旨在研究亲水性聚合物提高由HME处理的水溶性差的API的溶解速率的效率。选择吲哚美辛(INM)和法莫替丁(FMT)作为模型活性物质,而聚乙烯醇己内酰胺接枝共聚物,Soluplus®(SOL)和乙烯基吡咯烷酮-乙酸乙烯酯共聚物等级Kollidon®VA64(VA​​64)和Plasdone®S630(S630)被用作亲水性物质聚合物载体。出于研究的目的,所有不同比例的药物-聚合物二元共混物均由Randcastle单螺杆挤出机加工而成。通过X射线粉末衍射(XRPD),差示扫描量热法(DSC)和扫描电子显微镜(SEM)评估挤出物的理化性质和形态。 INM和FMT在特定浓度下表现出强大的增塑作用,并且发现其分子分散在聚合物共混物中。体外溶出度研究表明,与纯API相比,所有制剂的INM / FMT释放速率均增加。布洛芬还嵌入甲基丙烯酸酯共聚物(EPO)中,通过热熔挤出工艺生产固体分散体。将获得的颗粒掺入口腔崩解片(ODT)中。通过改变超崩解剂(如交联羧甲基纤维素钠和交联聚乙烯吡咯烷酮)的比例来开发片剂,同时使用直接压片工艺在各种压紧力下将ODT压片以优化片剂的坚固性。进一步评估了压制片剂的性能,包括孔隙率,硬度,脆性和溶出度,并与市售的Meltlet ODTs进行了比较。与Netupel Meltlets相比,挤出的ODTs的体外溶解显示布洛芬快速释放。检验了热熔挤出对乙酰氨基酚(PMOL)制剂的掩蔽效率的体外和体内评估。通过HME制备在Eudragit(EPO)或VA64(VA​​64)中含有高PMOL含量的挤出颗粒。类似地,将普萘洛尔HCl(PRP),苯海拉明HCl(DPD),西替利嗪HCl(CTZ)和维拉帕米HCl(VRP)用作模型阳离子活性物质,而基于pH敏感的基于甲基丙烯酸甲酯的丙烯酸甲基丙烯酸甲酯共​​聚物L100(L100)和丙烯酸乙酯共聚物L100-55(Acryl-EZE®)(L100-55)被用作聚合物载体,以生产掩盖味道的挤出配方,从而确定药物-聚合物之间的分子间相互作用。由六名健康人类志愿者组成的小组在体内评估了加工过的制剂的掩味效果。此外,还分别通过配备7个传感器的Astree电子舌(Alpha MOS)和味觉传感系统TS5000Z(INSENT)进行了体外评估。 ud ud对人类志愿者的味道和感官评估表明,该配方被掩盖了API的苦味和改善的片剂适口性。除此之外,通过将安慰剂聚合物和纯API的数据相互关联,味道感测技术证明了所有聚合物的味道都有改善。电子舌的结果与体内评价非常吻合。分子建模(Gaussian 09)预测了两种可能的H键类型的存在,而傅立叶变换红外(FT-IR)和NMR研究证实了这两种组分(阳离子药物-阴离子聚合物)的官能团之间的药物-聚合物相互作用。此外,通过Flory-Huggins相互作用参数理论和X射线光电子能谱(XPS)评估的分子间相互作用显示,与L100-55系统相比,L100系统中药物-聚合物之间的相互作用更强。这项研究得出的分子间相互作用的机理表明,活性物质的胺基与聚合物中的羧基之间存在氢键。 N10)或乙基纤维素Premium 7(EC P7),以开发由HME处理的缓释片剂。随后将压制的片剂用肠溶衣聚合物S100(15-20%)包衣,该聚合物在12小时内显示出持续释放,滞后时间为2小时。通过实施五种不同的动力学释放模型对HCS从片剂中释放的机理进行了进一步分析,这些模型证实了HCS从包衣和未包衣片剂中的释放均遵循一级动力学模型。

著录项

  • 作者

    Maniruzzaman Mohammed;

  • 作者单位
  • 年度 2012
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号